Quarterly ResultApr 28, 2026, 07:08 AM
INCY Q1 Revenue +21% to $1.27B; Net Sales +20% to $1.10B
AI Summary
Incyte reported strong Q1 2026 financial results with total revenue increasing 21% to $1.27 billion and total net sales rising 20% to $1.10 billion year-over-year. The company saw significant growth in product sales, particularly Opzelura (+20%), Niktimvo (+305%), and Zynyz (+1,276%). Key business updates include positive Phase 3 results for povorcitinib in nonsegmental vitiligo, NDA acceptance for povorcitinib in hidradenitis suppurativa, and four anticipated approvals/launches from mid-2026 into early 2027. Incyte also reaffirmed its full-year 2026 financial guidance and announced new executive appointments.
Key Highlights
- Total revenue increased 21% to $1.27 billion in Q1 2026 vs. Q1 2025.
- Total net sales rose 20% to $1.10 billion in Q1 2026 vs. Q1 2025.
- Jakafi net sales grew 7% to $758 million; Opzelura net sales increased 20% to $143 million.
- Hematology and Oncology portfolio net sales surged 116% to $204 million.
- GAAP net income was $303.3 million ($1.47 diluted EPS) in Q1 2026, up from $158.2 million ($0.80 diluted EPS) in Q1 2025.
- Cash, cash equivalents, and marketable securities totaled $4.0 billion as of March 31, 2026.
- Povorcitinib achieved primary endpoint in Phase 3 nonsegmental vitiligo studies (F-VASI75 >75% reduction).
- FDA accepted NDA for povorcitinib in moderate to severe hidradenitis suppurativa.
- Company reaffirmed 2026 financial guidance: total net sales $4.77B-$4.94B.